Due to its regulatory role in the IGF signaling system, IGFBP4 has emerged as a potential biomarker in various pathological conditions, such as cancer [61], cardiovascular diseases [62], and metabolic disorders [63]. This evidence concerns the gene IGF1 and cancer.